Monoclonal antibodies to the CD25 (IL-2a) receptors are used for a treatment of:: (A) Hematological neoplasm, (B) Autoimmune disease, (C) Bone marrow transplantation, (D) Kidney transplant rejection
Answer is D. (Antibodies to CD 25) -Basiliximab reduces the incidence and severity of acute rejection in kidney transplantation without increasing the incidence of oppounistic infections.